A Phase 3 interventional study of Insulin degludec/insulin aspart and Insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 71 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-13.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 6 that started in 2016, is one of 49 in phase 3, and was the 50th registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 532 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
644 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 26 open now, 30 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 644 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 87th largest by enrollment of the 429 interventional ones that give a count, is one of 20 that started in 2016, is one of 187 in phase 3, and was the 423rd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 644 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
This study's enrollment of 532 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Insulin degludec/insulin aspart
Drug: Insulin glargine · Drug: Insulin aspart
Drug pages: Insulin degludec · Insulin Aspart
Administered subcutaneously (s.c. under the skin) once daily.
Administered subcutaneously (s.c. under the skin) once daily.
Administered subcutaneously (s.c. under the skin) once daily.
Change in HbA1c (%) - Week 26
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated 26 weeks after randomisation.
Time frame: Week 0, week 26
Change in HbA1c (%) - Week 38
Change from baseline (week 0) in HbA1c was evaluated 38 weeks after randomisation.
Time frame: Week 0, week 38
Responder (Yes/No) for HbA1c < 7%
Participants achieving (yes/no) HbA1c \<7% was evaluated 26 and 38 weeks after randomisation, respectively.
Time frame: Week 26 and week 38
Responder (Yes/No) for HbA1c <7% Without Severe or BG Confirmed Symptomatic Hypoglycaemia
Participants achieving (yes/no) HbA1c \<7% without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia, was evaluated 26 and 38 weeks after randomisation, respectively. Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time frame: Week 26 and week 38
Change in FPG
Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated 26 and 38 weeks after randomisation, respectively.
Time frame: Week 0, week 26, week 38
Change in Pre-breakfast SMPG (Used for Titration)
Reported results are observed pre-breakfast self-measured plasma glucose (SMPG; used for titration) values at week 1 (baseline) and 26 and 38 weeks after randomisation.
Time frame: Week 1, week 26, week 38
Change in Postprandial SMPG Increment (From 9-point Profile)
Change from baseline (week 0) in postprandial SMPG increment (from 9-point profile) was evaluated 26 and 38 weeks after randomisation, respectively. 9-point SMPG profiles were measured starting in the morning 2 days prior to the scheduled visit at the time points described below: 1) Before breakfast (2 days prior to visit) 2) 90 minutes after start of the breakfast 3) Before lunch 4) 90 minutes after start of the lunch 5) Before dinner/main evening meal 6) 90 minutes after start of the dinner/main evening meal 7) At bedtime (2 days or 1 day prior to visit depending on actual clock time) 8) At 4 a.m. (1 day prior to visit) 9) Before breakfast at the following day (1 day prior to the visit).
Time frame: Week 0, week 26, week 38
Number of Nocturnal, Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Number of nocturnal, treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were analysed during the following periods: weeks 0-26, weeks 16-26 and weeks 0-38. Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05:59 both inclusive. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product.
Time frame: Weeks 0-26, weeks 16-26, weeks 0-38
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were analysed during the following periods: weeks 0-26, weeks 16-26 and weeks 0-38. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product.
Time frame: Weeks 0-26, weeks 16-26, weeks 0-38
Total Insulin Dose
Total insulin dose was evaluated 26 and 38 weeks after randomisation, respectively.
Time frame: Week 26 and week 38
Change in Body Weight
Change from baseline (week 0) in body weight was evaluated 26 and 38 weeks after randomisation, respectively.
Time frame: Week 0, week 26, week 38
Incidence of TEAEs
Number of treatment emergent adverse events (TEAEs) were analysed during the following periods: weeks 0-26, weeks 26-38 and weeks 0-38. Treatment emergent: An adverse event that had an onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. If an event had an onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period, or if it had an onset date within 7 days after the last drug date, then this event was also to be considered as a TEAE.
Time frame: Weeks 0-26, weeks 26-38, weeks 0-38
The trial was conducted at 71 sites in 7 countries, as follows: Algeria (4), Czech Republic (6), India (10), Russian Federation (11), Serbia (5), Turkey (7), and United States (28). Additionally, 1 site in the United States screened, but didn't randomise any subject.
| Milestone | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Started | 267 | 265 |
| Exposed | 265 | 263 |
| Completed | 261 | 254 |
| Not completed | 6 | 11 |
| Withdrew: Unclassified | 1 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 4 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Milestone | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Started | 261 | 254 |
| Completed | 252 | 247 |
| Not completed | 9 | 7 |
| Withdrew: Unclassified | 3 | 2 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 |
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated 26 weeks after randomisation.
| % of HbA1c | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Baseline (week 0) | 8.2 ± 0.8 | 8.1 ± 0.7 |
| Change from baseline (week 26) | -1.1 ± 0.9 | -1.1 ± 0.8 |
Change from baseline (week 0) in HbA1c was evaluated 38 weeks after randomisation.
| % of HbA1c | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Baseline (week 0) | 8.2 ± 0.8 | 8.1 ± 0.7 |
| Change from baseline (week 38) | -1.2 ± 0.9 | -1.2 ± 0.9 |
Participants achieving (yes/no) HbA1c \<7% was evaluated 26 and 38 weeks after randomisation, respectively.
| Number of participants | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Week 26: Yes | 120 | 120 |
| Week 26: No | 121 | 122 |
| Week 38: Yes | 139 | 140 |
| Week 38: No | 95 | 93 |
Participants achieving (yes/no) HbA1c \<7% without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia, was evaluated 26 and 38 weeks after randomisation, respectively. Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
| Number of participants | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Week 26: Yes | 73 | 61 |
| Week 26: No | 168 | 181 |
| Week 38: Yes | 60 | 56 |
| Week 38: No | 174 | 177 |
Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated 26 and 38 weeks after randomisation, respectively.
| mg/dL | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Baseline: Week 0 | 162.4 ± 47.8 | 157.8 ± 47.8 |
| Change from baseline: Week 26 | -42.1 ± 52.1 | -40.6 ± 59.2 |
| Change from baseline: Week 38 | -48.6 ± 54.2 | -41.5 ± 55.3 |
Reported results are observed pre-breakfast self-measured plasma glucose (SMPG; used for titration) values at week 1 (baseline) and 26 and 38 weeks after randomisation.
| mg/dL | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Week 1 (Baseline) | 158.3 ± 45.7 | 149.4 ± 43.8 |
| Week 26 | 107.5 ± 24.8 | 103.4 ± 20.7 |
| Week 38 | 102.9 ± 20.0 | 103.8 ± 22.5 |
Change from baseline (week 0) in postprandial SMPG increment (from 9-point profile) was evaluated 26 and 38 weeks after randomisation, respectively. 9-point SMPG profiles were measured starting in the morning 2 days prior to the scheduled visit at the time points described below: 1) Before breakfast (2 days prior to visit) 2) 90 minutes after start of the breakfast 3) Before lunch 4) 90 minutes after start of the lunch 5) Before dinner/main evening meal 6) 90 minutes after start of the dinner/main evening meal 7) At bedtime (2 days or 1 day prior to visit depending on actual clock time) 8) At 4 a.m. (1 day prior to visit) 9) Before breakfast at the following day (1 day prior to the visit).
| mg/dL | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Baseline: Week 0 | 54.5 ± 37.7 | 48.4 ± 38.0 |
| Change from baseline: Week 26 | -10.8 ± 46.3 | -8.7 ± 40.6 |
| Change from baseline: Week 38 | -17.7 ± 40.0 | -19.7 ± 45.0 |
Number of nocturnal, treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were analysed during the following periods: weeks 0-26, weeks 16-26 and weeks 0-38. Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05:59 both inclusive. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product.
| Episodes | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Weeks 0-26 | 61 | 118 |
| Weeks 16-26 | 24 | 58 |
| Weeks 0-38 | 113 | 189 |
Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were analysed during the following periods: weeks 0-26, weeks 16-26 and weeks 0-38. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product.
| Episodes | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Weeks 0-26 | 329 | 376 |
| Weeks 16-26 | 154 | 194 |
| Weeks 0-38 | 537 | 640 |
Total insulin dose was evaluated 26 and 38 weeks after randomisation, respectively.
| Units | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Week 26 | 70.9 ± 41.5 | 79.4 ± 37.7 |
| Week 38 | 83.4 ± 51.3 | 89.3 ± 43.1 |
Change from baseline (week 0) in body weight was evaluated 26 and 38 weeks after randomisation, respectively.
| Kg | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Baseline: Week 0 | 88.5 ± 18.6 | 88.4 ± 17.5 |
| Change from basline: Week 26 | 1.7 ± 3.2 | 1.4 ± 3.2 |
| Change from basline: Week 38 | 2.5 ± 3.8 | 2.4 ± 3.2 |
Number of treatment emergent adverse events (TEAEs) were analysed during the following periods: weeks 0-26, weeks 26-38 and weeks 0-38. Treatment emergent: An adverse event that had an onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. If an event had an onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period, or if it had an onset date within 7 days after the last drug date, then this event was also to be considered as a TEAE.
| Events | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Weeks 0-26 | 441 | 408 |
| Weeks 26-38 | 173 | 117 |
| Weeks 0-38 | 614 | 525 |
Collected over Week 0 to week 38 (treatment period) + 7 days (follow-up period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec/Insulin Aspart | 0/265 (0%) | 18/265 (6.8%) | 74/265 (27.9%) |
| Insulin Glargine + Insulin Aspart | 2/263 (0.8%) | 20/263 (7.6%) | 57/263 (21.7%) |
| Event | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/265 | 2/263 |
| VertigoEar and labyrinth disorders | 0/265 | 2/263 |
| Coronary artery diseaseCardiac disorders | 2/265 | 1/263 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/265 | 1/263 |
| Acute myocardial infarctionCardiac disorders | 1/265 | 1/263 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/265 | 1/263 |
| Adrenal massEndocrine disorders | 0/265 | 1/263 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/265 | 1/263 |
| BronchitisInfections and infestations | 0/265 | 1/263 |
| CholecystectomySurgical and medical procedures | 0/265 | 1/263 |
| Event | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart |
|---|---|---|
| NasopharyngitisInfections and infestations | 36/265 | 22/263 |
| HeadacheNervous system disorders | 27/265 | 16/263 |
| Upper respiratory tract infectionInfections and infestations | 15/265 | 17/263 |
| Back painMusculoskeletal and connective tissue disorders | 16/265 | 9/263 |
Full analysis set (FAS), which included all randomised subjects.
| Age, Continuous(Years) | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart | Total |
|---|---|---|---|
| Mean | 58.2 ± 8.9 | 59.2 ± 9.1 | 58.7 ± 9.0 |
| Sex: Female, Male(Participants) | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart | Total |
|---|---|---|---|
| Female | 142 | 128 | 270 |
| Male | 125 | 137 | 262 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 20 | 41 |
| Not Hispanic or Latino | 246 | 245 | 491 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Insulin Degludec/Insulin Aspart | Insulin Glargine + Insulin Aspart | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 29 | 32 | 61 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 11 | 24 |
| White | 221 | 220 | 441 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Aug 2017, 11 months.
Results were first posted in Sep 2018, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 11 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart